NVAX — Novavax, Inc.
$8.53
$-0.24 (-2.68%)
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Market Cap
$1.41B
Forward P/E
-47.4x
52-Week Range
N/A
NVAX Price History
Revenue vs. Net Income
$1.1B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$251M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
64.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.9x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.6%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+13.7%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
